GSK buys RAPT Therapeutics for $2.2 billion. With this takeover, it acquires a manufacturer of drugs for the treatment of food allergies. It is an experimental drug for food allergies. GSK will pay $58 for one share of RAPT Therapeutics. This price represents a 65% premium over the previous day's closing share price. The deal was announced in connection with the strengthening of GSK's allergy portfolio.